Jacobs Levy Equity Management
ALXO icon

Jacobs Levy Equity Management’s ALX Oncology ALXO Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.8K Buy
+25,507
New +$45.6K ﹤0.01% 929
2024
Q3 		– Sell
-232,022
Closed -$1.4M – 949
2024
Q2 		$1.4M Buy
+232,022
New +$2.85M 0.01% 668

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Jacobs Levy Equity Management's ALXO Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in ALX Oncology (ALXO) in Q2 2026: 25,507 shares worth $52.8K. The stake represents ﹤0.01% of the portfolio and ranks #929 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in ALXO as recently as Q2 2024.

Jacobs Levy Equity Management first reported a position in ALXO in Q2 2024 and has held it in 2 quarters since. The position peaked at $1.4M in Q2 2024. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Jacobs Levy Equity Management held 25,507 shares of ALX Oncology worth $52.8K as of Q2 2026.
  • ALX Oncology was a new Jacobs Levy Equity Management position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #929 holding.
  • Jacobs Levy Equity Management first reported a position in ALX Oncology in Q2 2024 and has held it in 2 quarters since.
  • Jacobs Levy Equity Management's ALX Oncology position peaked at $1.4M in Q2 2024.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.